Could a single drug infusion limit permanent heart damage during a heart attack?
NCT ID NCT07502521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called dexrazoxane, given through a vein, can reduce permanent heart muscle damage in people having a severe heart attack (STEMI). Fifty adults received either the drug or a placebo during their standard stent procedure. The goal was to see if the drug could limit bleeding and scarring in the heart, helping it pump better afterward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION (AMI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Synergy Cardiovascular Research Center
Rajkot, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a temporary heart pump save more lives in cardiogenic shock?
- Can a Community-Based rehab program boost heart recovery after a first attack?
- AI on a simple ECG: a new way to gauge heart attack severity?
- Can a diabetes drug shield the heart during a heart attack procedure?
- Smartphone apps and wearables could transform heart recovery
- Could aging clues in the blood predict heart attack recovery?